Press release
Dermatomyositis Clinical Trials and Pipeline Assessment: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approvals, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Dermatomyositis Clinical Trials
As per DelveInsight's assessment, globally, Dermatomyositis pipeline constitutes 10+ key companies continuously working towards developing 10+ Dermatomyositis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
Request for Sample Report here @ Dermatomyositis Pipeline Outlook - https://www.delveinsight.com/report-store/dermatomyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Dermatomyositis Pipeline Report:
• Dermatomyositis Companies across the globe are diligently working toward developing novel Dermatomyositis treatment therapies with a considerable amount of success over the years.
• Dermatomyositis companies working in the treatment market are Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals, others are developing therapies for the Dermatomyositis treatment.
• Emerging Dermatomyositis therapies such as EFG PH20, KZR-616, and others are expected to have a significant impact on the Dermatomyositis market in the coming years.
• In June 2024, Priovant Therapeutics, Inc announced results of a A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Dermatomyositis
• In June 2024, Galapagos announced results of a Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GLPG3667 Once Daily for 24 Weeks in Adult Subjects With Dermatomyositis
• In July 2024, CSL Behring announced a Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults With Dermatomyositis (DM) - The RECLAIIM Study
• In June 2024, argenx announced results of a Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart in Adults With Dermatomyositis
• In June 2024, AstraZeneca announced results of a Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Dermatomyositis Overview
Dermatomyositis (DM) is a rare autoimmune disease characterized by chronic muscle inflammation and distinctive skin rashes. It primarily affects adults and children, with a higher prevalence in women. The exact cause remains unknown, but it is believed to result from an abnormal immune response, genetic predisposition, and possible environmental triggers, including viral infections and malignancies.
The hallmark symptoms of dermatomyositis include progressive muscle weakness, typically in the shoulders, hips, and neck, making activities like climbing stairs or lifting objects difficult. Skin manifestations include a purple or reddish rash on the face, eyelids, knuckles, elbows, and knees, along with Gottron's papules and heliotrope rash. Other symptoms may include fatigue, joint pain, difficulty swallowing (dysphagia), and lung complications.
Diagnosis is based on clinical evaluation, muscle enzyme tests (elevated creatine kinase), electromyography (EMG), muscle biopsy, and autoantibody testing. Magnetic resonance imaging (MRI) may also help assess muscle inflammation.
Treatment focuses on reducing inflammation and managing symptoms. First-line therapy includes corticosteroids and immunosuppressants like methotrexate or azathioprine. In refractory cases, intravenous immunoglobulin (IVIG) and biologics such as rituximab may be used. Physical therapy and sun protection are also crucial in managing the disease and improving quality of life.
Get a Free Sample PDF Report to know more about Dermatomyositis Pipeline Therapeutic Assessment- Dermatomyositis Drugs in Pipeline - https://www.delveinsight.com/sample-request/dermatomyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Dermatomyositis Route of Administration
Dermatomyositis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
Dermatomyositis Molecule Type
Dermatomyositis Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Dermatomyositis Pipeline Therapeutics Assessment
• Dermatomyositis Assessment by Product Type
• Dermatomyositis By Stage and Product Type
• Dermatomyositis Assessment by Route of Administration
• Dermatomyositis By Stage and Route of Administration
• Dermatomyositis Assessment by Molecule Type
• Dermatomyositis by Stage and Molecule Type
DelveInsight's Dermatomyositis Clinical Trials Report covers around 10+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Dermatomyositis product details are provided in the report. Download the Dermatomyositis pipeline report to learn more about the emerging Dermatomyositis therapies- Dermatomyositis Therapeutics Market - https://www.delveinsight.com/report-store/dermatomyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Dermatomyositis Pipeline Analysis:
The Dermatomyositis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Dermatomyositis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dermatomyositis Treatment.
• Dermatomyositis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dermatomyositis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dermatomyositis market.
Download Sample PDF Report to know more about Dermatomyositis drugs and therapies- Dermatomyositis Clinical trials and FDA Approvals - https://www.delveinsight.com/sample-request/dermatomyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of Dermatomyositis Pipeline Drug Insight
• Coverage: Global
• Key Dermatomyositis Companies: Kezar Life Sciences, Argenx, Pfizer, CSL Behring, Viela Bio, PAEAN Biotechnology, Alexion Pharmaceuticals, others.
• Key Dermatomyositis Therapies: EFG PH20, KZR-616, and others.
• Dermatomyositis Therapeutic Assessment: Dermatomyositis current marketed and Dermatomyositis emerging therapies
• Dermatomyositis Market Dynamics: Dermatomyositis market drivers and Dermatomyositis market barriers
Request for Sample PDF Report for Dermatomyositis Pipeline Assessment and clinical trials - Dermatomyositis Drugs and Therapies - https://www.delveinsight.com/sample-request/dermatomyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Dermatomyositis Report Introduction
2. Dermatomyositis Executive Summary
3. Dermatomyositis Overview
4. Dermatomyositis- Analytical Perspective In-depth Commercial Assessment
5. Dermatomyositis Pipeline Therapeutics
6. Dermatomyositis Late Stage Products (Phase II/III)
7. Dermatomyositis Mid Stage Products (Phase II)
8. Dermatomyositis Early Stage Products (Phase I)
9. Dermatomyositis Preclinical Stage Products
10. Dermatomyositis Therapeutics Assessment
11. Dermatomyositis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Dermatomyositis Companies
14. Dermatomyositis Key Products
15. Dermatomyositis Unmet Needs
16 . Dermatomyositis Market Drivers and Barriers
17. Dermatomyositis Future Perspectives and Conclusion
18. Dermatomyositis Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market-forecast
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Xerostomia Market: https://www.delveinsight.com/whitepaper-newsletter/xerostomia-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/osteoarthritis-market
• Brain/cranial Implants Market: https://www.delveinsight.com/report-store/brain-implants-market-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Pharma Competitive Intelligence: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Surgical Site Infections Market: https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiac Resynchronization Therapy Device Market: https://www.delveinsight.com/report-store/cardiac-resynchronization-therapy-market
• Central Retinal Venous Occlusion Market: https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
• Cerebral Vein Thrombosis Market: https://www.delveinsight.com/report-store/cerebral-vein-thrombosis-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Febrile Neutropenia Market: https://www.delveinsight.com/report-store/febrile-neutropenia-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage
Case study: https://www.delveinsight.com/case-study/go-to-market-strategy
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dermatomyositis Clinical Trials and Pipeline Assessment: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approvals, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight here
News-ID: 3865943 • Views: …
More Releases from DelveInsight Business Research
Immune Checkpoint Inhibitors Market Outlook 2034: Competitive Landscape, Pipelin …
DelveInsight's latest report, "Immune Checkpoint Inhibitors Market Forecast (2020-2034)", provides an in-depth analysis of one of the most transformative areas in oncology. According to DelveInsight estimates, the Immune Checkpoint Inhibitors (ICI) market is expected to grow at a decent CAGR throughout the forecast period, driven by the rising global burden of cancer, advances in immuno-oncology, increasing healthcare expenditures, and the anticipated approval of novel ICIs across the 7MM [the United…
HPK1 Inhibitors Market Outlook 2034: Competitive Landscape, Pipeline Advancement …
(Albany, USA, September 2025) - DelveInsight has released its latest report, "HPK1 Inhibitor Competitive Landscape And Market Forecast - 2034," delivering an in-depth analysis of the rapidly evolving HPK1 inhibitor market. The report offers a comprehensive overview of the epidemiology, drug uptake, treatment landscape, competitive intelligence, and market dynamics shaping the outlook of HPK1 inhibitors across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To know…
Focal Adhesion Kinase (FAK) Inhibitors Market Outlook 2034: Scientific Advances, …
(Albany, USA, September 2025) - Focal Adhesion Kinase (FAK), also known as PTK2, has emerged as one of the most promising molecular targets in oncology research and therapy development. Encoded by the PTK2 gene, FAK is a non-receptor tyrosine kinase critically involved in signal transduction mediated by growth factor receptors and integrins. Increasing evidence shows that overexpression of FAK is directly associated with tumor progression, therapy resistance, and poor clinical…
Thyroid Eye Disease Market Set for Robust Expansion Through 2034, DelveInsight R …
DelveInsight's "Thyroid Eye Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Thyroid Eye Disease, historical and forecasted epidemiology as well as the Thyroid Eye Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Thyroid Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Thyroid Eye Disease…
More Releases for Dermatomyositis
Dermatomyositis market expected to reach USD 1.2 billion by 2034
Dermatomyositis is a rare, chronic autoimmune condition characterized by muscle inflammation and distinctive skin rashes. The disease impacts both adults and children, with complications that include interstitial lung disease and increased cancer risk. Despite its rarity, dermatomyositis places a significant burden on patients due to disability, reduced quality of life, and high treatment costs.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71381
In recent years, the dermatomyositis market has seen…
Dermatomyositis Market to Witness Promising Upswing by 2034, DelveInsight Foreca …
DelveInsight's "Dermatomyositis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dermatomyositis, historical and forecasted epidemiology as well as the Dermatomyositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Dermatomyositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dermatomyositis Market Forecast
https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Dermatomyositis…
Dermatomyositis (DM) Market Emerging Trends and Growth Prospects 2034
Introduction
Dermatomyositis (DM) is a rare, chronic autoimmune inflammatory myopathy characterized by muscle weakness and distinctive skin rashes. It affects both adults and children and is associated with complications such as interstitial lung disease, malignancies, and cardiovascular involvement. The disease significantly reduces patient quality of life and requires long-term medical care.
Historically treated with corticosteroids and immunosuppressants, the market is now evolving with biologics, monoclonal antibodies, and targeted immunotherapies. Increasing global awareness…
Dermatomyositis Treatment Market Growth Accelerates: Strategic Forecast Predicts …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Dermatomyositis Treatment Industry Market Size Be by 2025?
The market for dermatomyositis treatment has seen significant expansion in the past few years. It is projected to escalate from $0.85 billion in 2024 to $0.91 billion in 2025, representing a compound annual growth rate (CAGR) of 7.2%.…
Dermatomyositis Market - Defying the challenges of dermatomyositis: choose our t …
Newark, New Castle, USA: The "Dermatomyositis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Dermatomyositis Market: https://www.growthplusreports.com/report/dermatomyositis-market/8675
This latest report researches the industry structure, sales, revenue, price and…
Dermatomyositis Market Size, Analysis, Share, Research, Business Growth and Fore …
Dermatomyositis Market 2021 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Dermatomyositis industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2021 to 2031 time period. It presents a close overview of the…
